Literature DB >> 7548699

Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.

S S Emerson1.   

Abstract

In the conduct of a clinical trial, unexpectedly high rates of toxicity may cause a researcher to want to terminate the trial early even though no formal stopping rule had been specified. The experience of one such clinical trial is used as an example of the ways in which group sequential methodology can be applied in deciding to stop the study, as well as in reporting the results of the clinical trial. This approach is then compared to a Bayesian analysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548699

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  3 in total

1.  Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.

Authors:  Marianne Sponer Muhlebach; Valeria Beckett; Elena Popowitch; Melissa B Miller; Arthur Baines; Nicole Mayer-Hamblett; Edith T Zemanick; Wynton C Hoover; Jill M VanDalfsen; Preston Campbell; Christopher H Goss
Journal:  Thorax       Date:  2016-11-15       Impact factor: 9.139

2.  ADAPT: the wrong way to stop a clinical trial.

Authors:  Steven E Nissen
Journal:  PLoS Clin Trials       Date:  2006-11-17

Review 3.  Interim analysis: A rational approach of decision making in clinical trial.

Authors:  Amal Kumar; Bhaswat S Chakraborty
Journal:  J Adv Pharm Technol Res       Date:  2016 Oct-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.